The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy

Ying En Lee, Hong Lin He, Yow Ling Shiue, Sung Wei Lee, Li Ching Lin, Ting Feng Wu, I. Wei Chang, Hao Hsien Lee, Chien Feng Li

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Neoadjuvant concurrent chemoradiotherapy has been widely used for rectal cancer to improve local tumor control. The varied response of individual tumors encouraged us to search for useful biomarkers to predict the therapeutic response. The study was aimed to evaluate the prognostic impact of lipid biosynthesis-associated biomarkers in rectal cancer patients treated with preoperative chemoradiotherapy. Through analysis of the previously published gene expression profiling database focusing on genes associated with lipid biosynthesis, we found that HSD17B2 and HMGCS2 were the top two significantly upregulated genes in the non-responders. We further evaluated their expression by immunohistochemistry in the pre-treatment tumor specimens from 172 patients with rectal cancer and statistically analyzed the associations between their expression and various clinicopathological factors, as well as survival. High expression of HMGCS2 or HSD17B2 was significantly associated with advanced pre- and post-treatment tumor or nodal status (P < 0.001) and lower tumor regression grade (P < 0.001). More importantly, high expression of either HMGCS2 or HSD17B2 was of prognostic significance, with HMGCS2 overexpression indicating poor prognosis for disease-free survival (P = 0.0003), local recurrence-free survival (P = 0.0115), and metastasis-free survival (P = 0.0119), while HSD17B2 overexpression was associated with poor prognosis for disease-free survival (P <0.0001), local recurrence-free survival (P = 0.0009), and metastasis-free survival (P < 0.0001). In multivariate analysis, only HSD17B2 overexpression remained as an independent prognosticator for shorter disease-free survival (P < 0.001) and metastasis-free survival (P = 0.008). In conclusion, high expression of either HSD17B2 or HMGCS2 predicted poor susceptibility of rectal cancer to preoperative chemoradiotherapy. Both acted as promising prognostic factors, particularly HSD17B2.

Original languageEnglish
Pages (from-to)7675-7683
Number of pages9
JournalTumor Biology
Volume36
Issue number10
DOIs
Publication statusPublished - Sep 1 2015
Externally publishedYes

Fingerprint

Chemoradiotherapy
Rectal Neoplasms
Lipids
Survival
Disease-Free Survival
Neoplasms
Neoplasm Metastasis
Biomarkers
Recurrence
Gene Expression Profiling
Therapeutics
Genes
Multivariate Analysis
Immunohistochemistry
Databases

Keywords

  • CCRT
  • Chemoradiotherapy
  • HMGCS2
  • HSD17B2
  • Rectal cancer

ASJC Scopus subject areas

  • Cancer Research

Cite this

The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy. / Lee, Ying En; He, Hong Lin; Shiue, Yow Ling; Lee, Sung Wei; Lin, Li Ching; Wu, Ting Feng; Chang, I. Wei; Lee, Hao Hsien; Li, Chien Feng.

In: Tumor Biology, Vol. 36, No. 10, 01.09.2015, p. 7675-7683.

Research output: Contribution to journalArticle

Lee, Ying En ; He, Hong Lin ; Shiue, Yow Ling ; Lee, Sung Wei ; Lin, Li Ching ; Wu, Ting Feng ; Chang, I. Wei ; Lee, Hao Hsien ; Li, Chien Feng. / The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy. In: Tumor Biology. 2015 ; Vol. 36, No. 10. pp. 7675-7683.
@article{0fdd7d3e868146fe89c9b7849e99a6f0,
title = "The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy",
abstract = "Neoadjuvant concurrent chemoradiotherapy has been widely used for rectal cancer to improve local tumor control. The varied response of individual tumors encouraged us to search for useful biomarkers to predict the therapeutic response. The study was aimed to evaluate the prognostic impact of lipid biosynthesis-associated biomarkers in rectal cancer patients treated with preoperative chemoradiotherapy. Through analysis of the previously published gene expression profiling database focusing on genes associated with lipid biosynthesis, we found that HSD17B2 and HMGCS2 were the top two significantly upregulated genes in the non-responders. We further evaluated their expression by immunohistochemistry in the pre-treatment tumor specimens from 172 patients with rectal cancer and statistically analyzed the associations between their expression and various clinicopathological factors, as well as survival. High expression of HMGCS2 or HSD17B2 was significantly associated with advanced pre- and post-treatment tumor or nodal status (P < 0.001) and lower tumor regression grade (P < 0.001). More importantly, high expression of either HMGCS2 or HSD17B2 was of prognostic significance, with HMGCS2 overexpression indicating poor prognosis for disease-free survival (P = 0.0003), local recurrence-free survival (P = 0.0115), and metastasis-free survival (P = 0.0119), while HSD17B2 overexpression was associated with poor prognosis for disease-free survival (P <0.0001), local recurrence-free survival (P = 0.0009), and metastasis-free survival (P < 0.0001). In multivariate analysis, only HSD17B2 overexpression remained as an independent prognosticator for shorter disease-free survival (P < 0.001) and metastasis-free survival (P = 0.008). In conclusion, high expression of either HSD17B2 or HMGCS2 predicted poor susceptibility of rectal cancer to preoperative chemoradiotherapy. Both acted as promising prognostic factors, particularly HSD17B2.",
keywords = "CCRT, Chemoradiotherapy, HMGCS2, HSD17B2, Rectal cancer",
author = "Lee, {Ying En} and He, {Hong Lin} and Shiue, {Yow Ling} and Lee, {Sung Wei} and Lin, {Li Ching} and Wu, {Ting Feng} and Chang, {I. Wei} and Lee, {Hao Hsien} and Li, {Chien Feng}",
year = "2015",
month = "9",
day = "1",
doi = "10.1007/s13277-015-3503-2",
language = "English",
volume = "36",
pages = "7675--7683",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "10",

}

TY - JOUR

T1 - The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy

AU - Lee, Ying En

AU - He, Hong Lin

AU - Shiue, Yow Ling

AU - Lee, Sung Wei

AU - Lin, Li Ching

AU - Wu, Ting Feng

AU - Chang, I. Wei

AU - Lee, Hao Hsien

AU - Li, Chien Feng

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Neoadjuvant concurrent chemoradiotherapy has been widely used for rectal cancer to improve local tumor control. The varied response of individual tumors encouraged us to search for useful biomarkers to predict the therapeutic response. The study was aimed to evaluate the prognostic impact of lipid biosynthesis-associated biomarkers in rectal cancer patients treated with preoperative chemoradiotherapy. Through analysis of the previously published gene expression profiling database focusing on genes associated with lipid biosynthesis, we found that HSD17B2 and HMGCS2 were the top two significantly upregulated genes in the non-responders. We further evaluated their expression by immunohistochemistry in the pre-treatment tumor specimens from 172 patients with rectal cancer and statistically analyzed the associations between their expression and various clinicopathological factors, as well as survival. High expression of HMGCS2 or HSD17B2 was significantly associated with advanced pre- and post-treatment tumor or nodal status (P < 0.001) and lower tumor regression grade (P < 0.001). More importantly, high expression of either HMGCS2 or HSD17B2 was of prognostic significance, with HMGCS2 overexpression indicating poor prognosis for disease-free survival (P = 0.0003), local recurrence-free survival (P = 0.0115), and metastasis-free survival (P = 0.0119), while HSD17B2 overexpression was associated with poor prognosis for disease-free survival (P <0.0001), local recurrence-free survival (P = 0.0009), and metastasis-free survival (P < 0.0001). In multivariate analysis, only HSD17B2 overexpression remained as an independent prognosticator for shorter disease-free survival (P < 0.001) and metastasis-free survival (P = 0.008). In conclusion, high expression of either HSD17B2 or HMGCS2 predicted poor susceptibility of rectal cancer to preoperative chemoradiotherapy. Both acted as promising prognostic factors, particularly HSD17B2.

AB - Neoadjuvant concurrent chemoradiotherapy has been widely used for rectal cancer to improve local tumor control. The varied response of individual tumors encouraged us to search for useful biomarkers to predict the therapeutic response. The study was aimed to evaluate the prognostic impact of lipid biosynthesis-associated biomarkers in rectal cancer patients treated with preoperative chemoradiotherapy. Through analysis of the previously published gene expression profiling database focusing on genes associated with lipid biosynthesis, we found that HSD17B2 and HMGCS2 were the top two significantly upregulated genes in the non-responders. We further evaluated their expression by immunohistochemistry in the pre-treatment tumor specimens from 172 patients with rectal cancer and statistically analyzed the associations between their expression and various clinicopathological factors, as well as survival. High expression of HMGCS2 or HSD17B2 was significantly associated with advanced pre- and post-treatment tumor or nodal status (P < 0.001) and lower tumor regression grade (P < 0.001). More importantly, high expression of either HMGCS2 or HSD17B2 was of prognostic significance, with HMGCS2 overexpression indicating poor prognosis for disease-free survival (P = 0.0003), local recurrence-free survival (P = 0.0115), and metastasis-free survival (P = 0.0119), while HSD17B2 overexpression was associated with poor prognosis for disease-free survival (P <0.0001), local recurrence-free survival (P = 0.0009), and metastasis-free survival (P < 0.0001). In multivariate analysis, only HSD17B2 overexpression remained as an independent prognosticator for shorter disease-free survival (P < 0.001) and metastasis-free survival (P = 0.008). In conclusion, high expression of either HSD17B2 or HMGCS2 predicted poor susceptibility of rectal cancer to preoperative chemoradiotherapy. Both acted as promising prognostic factors, particularly HSD17B2.

KW - CCRT

KW - Chemoradiotherapy

KW - HMGCS2

KW - HSD17B2

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=84944277771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944277771&partnerID=8YFLogxK

U2 - 10.1007/s13277-015-3503-2

DO - 10.1007/s13277-015-3503-2

M3 - Article

C2 - 25929810

AN - SCOPUS:84944277771

VL - 36

SP - 7675

EP - 7683

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 10

ER -